How I treat indolent lymphoma
- PMID: 17311989
- DOI: 10.1182/blood-2006-10-041863
How I treat indolent lymphoma
Abstract
Despite advances in treatment, there was little evidence until recently that this led to improvement in the survival of patients with indolent lymphoma, with patients continuing to have an unremitting course of relapse of disease. There appears to have been a change in the natural history of these diseases with the introduction of chemoimmunotherapy that may finally result in improvements in survival. With so many agents available for the treatment of indolent lymphomas, questions that have to be addressed include the following: is there still a role for a "watch-and-wait" approach in asymptomatic patients or should they be treated at diagnosis, what are the optimal first-line and salvage treatments, what is the role of maintenance therapy, and is there any role for stem cell transplantation in these diseases? No established treatment of choice has yet emerged, and many of these questions remain unresolved. It is highly likely that our treatment approaches will continue to evolve as the results of ongoing clinical trials are released and that improvement in outcome will result from identification of therapies that target the underlying pathophysiology of the diseases.
Similar articles
-
Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma.Anticancer Drugs. 2002 Nov;13 Suppl 2:S19-24. doi: 10.1097/00001813-200211002-00004. Anticancer Drugs. 2002. PMID: 12710587 Review.
-
Natural history of and therapy for the indolent non-Hodgkin's lymphomas.Semin Oncol. 1993 Oct;20(5 Suppl 5):75-88. Semin Oncol. 1993. PMID: 8211209 Review. No abstract available.
-
Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma.Curr Opin Hematol. 2007 Jul;14(4):360-8. doi: 10.1097/MOH.0b013e32818a6daf. Curr Opin Hematol. 2007. PMID: 17534162 Review.
-
Treatment of indolent lymphoma in Germany - results of a representative population-based survey.Clin Lymphoma Myeloma Leuk. 2011 Apr;11(2):204-11. doi: 10.1016/j.clml.2011.03.001. Epub 2011 Apr 8. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21575925
-
Indolent lymphomas: current and emerging treatment approaches.Clin Adv Hematol Oncol. 2006 Sep;4(9 Suppl 20):1-10; quiz 11-2. Clin Adv Hematol Oncol. 2006. PMID: 17139243
Cited by
-
A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States.J Manag Care Spec Pharm. 2019 Apr;25(4):437-446. doi: 10.18553/jmcp.2019.18259. Epub 2019 Jan 4. J Manag Care Spec Pharm. 2019. PMID: 30608008 Free PMC article.
-
Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study.Haematologica. 2023 Mar 1;108(3):822-832. doi: 10.3324/haematol.2022.281421. Haematologica. 2023. PMID: 36263843 Free PMC article.
-
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.Blood. 2014 May 29;123(22):3406-13. doi: 10.1182/blood-2013-11-538546. Epub 2014 Mar 10. Blood. 2014. PMID: 24615776 Free PMC article. Clinical Trial.
-
Follicular lymphoma in the United States: first report of the national LymphoCare study.J Clin Oncol. 2009 Mar 10;27(8):1202-8. doi: 10.1200/JCO.2008.18.1495. Epub 2009 Feb 9. J Clin Oncol. 2009. PMID: 19204203 Free PMC article.
-
PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma.Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):215-21. doi: 10.1007/s00259-014-2896-2. Epub 2014 Sep 20. Eur J Nucl Med Mol Imaging. 2015. PMID: 25239490
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
